HIV Infection Is Associated With a Less Aggressive Phenotype of Inflammatory Bowel Disease: A Multicenter Study of the ENEIDA Registry-Reference-Cited by-同舟云学术

HIV Infection Is Associated With a Less Aggressive Phenotype of Inflammatory Bowel Disease: A Multicenter Study of the ENEIDA Registry

Published:2024-07-15 Issue: Volume: Page:
ISSN:0002-9270
Container-title:American Journal of Gastroenterology
language:en
Short-container-title:Am J Gastroenterol

Author:

Calafat Margalida¹²^ORCID,Suria Carles³,Mesonero Francisco⁴^ORCID,de Francisco Ruth⁵^ORCID,Yagüe Caballero Carmen⁶^ORCID,de la Peña Luisa⁷^ORCID,Hernández-Camba Alejandro⁸^ORCID,Marcé Ainhoa⁹,Gallego Beatriz¹⁰^ORCID,Martín-Vicente Noelia¹¹^ORCID,Rivero Montserrat¹²^ORCID,Iborra Marisa¹³^ORCID,Guerra Iván¹⁴^ORCID,Carrillo-Palau Marta¹⁵^ORCID,Madero Lucía¹⁶,Burgueño Beatriz¹⁷^ORCID,Monfort David¹⁸,Torres Gisela¹⁹,Teller Marta²⁰,Ferrer Rosique Juan Ángel²¹,Vega Villaamil Pablo²²^ORCID,Roig Cristina²³^ORCID,Ponferrada-Diaz Angel²⁴^ORCID,Betoré Glaría Elena²⁵^ORCID,Zabana Yamile²²⁶^ORCID,Gisbert Javier P.²²⁷,Busquets David²⁸^ORCID,Alcaide Noelia²⁹,Camps Blau³⁰,Legido Jesús³¹,González-Vivo Maria³²^ORCID,Bosca-Watts Marta Maia³^ORCID,Pérez-Martínez Isabel⁵,Casas Deza Diego⁶^ORCID,Guardiola Jordi⁷^ORCID,Arranz Hernández Laura⁸^ORCID,Navarro Mercè⁹^ORCID,Gargallo-Puyuelo Carla J.²¹⁰,Cañete Fiorella¹²^ORCID,Mañosa Míriam¹²^ORCID,Domènech Eugeni¹²³³,

Affiliation:

1. Gastroenterology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain;

2. Gastroenterology Department, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain;

3. Gastroenterology Department, Hospital Clínic Universitari de València, Universitat de València, València, Spain;

4. Gastroenterology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain;

5. Gastroenterology Department, Hospital Universitario Central de Asturias (Oviedo), Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain;

6. Gastroenterology Department, Hospital Universitario Miguel Servet (Zaragoza) and Instituto de Investigación Sanitaria de Aragón (IISA), Zaragoza, Spain;

7. Gastroenterology Department, Hospital Universitari de Bellvitge (L'Hospitalet de Llobregat), Barcelona, Spain;

8. Gastroenterology Department, Hospital Universitario Nuestra Señora de Candelaria, Tenerife, Spain;

9. Gastroenterology Department, Hospital Universitari Moisès Broggi, Sant Joan Despí, Spain;

10. Gastroenterology Department, Hospital Clínico Universitario «Lozano Blesa» (Zaragoza), Instituto de Investigación Sanitaria, IIS Aragón, Zaragoza, Spain;

11. Gastroenterology Department, Hospital Universitario de Galdakao, Galdakao, Spain;

12. Gastroenterology Department, Hospital Universitario Marqués de Valdecilla (Santander), Instituto de Investigación Marqués de Valdecilla IDIVAL, Santander, Spain;

13. Gastroenterology Department, Hospital Universitari i Politècnic la Fe de València, València, Spain;

14. Gastroenterology Department, Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain;

15. Gastroenterology Department, Hospital Universitario de Canarias, La Laguna, Santa Cruz de Tenerife, Spain;

16. Gastroenterology Department, Hospital General Universitario Dr Balmis de Alicante (Alicante), ISABIAL, Alicante, Spain;

17. Gastroenterology Department, Hospital Universitario Rio Hortega, Valladolid, Spain;

18. Gastroenterology Department, Consorci Sanitari de Terrassa, Terrassa, Spain;

19. Gastroenterology Department, Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain;

20. Gastroenterology Department, Althaia, Xarxa Assistencial Universitària de Manresa, Manresa, Spain;

21. Gastroenterology Department, Hospital Universitario Fundación Alcorcón, Alcorcón, Spain;

22. Gastroenterology Department, Complexo Hospitalario Universitario de Ourense, Ourense, Spain;

23. Gastroenterology Department, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain;

24. Gastroenterology Department, Hospital Universitario Infanta Leonor, Madrid, Spain;

25. Gastroenterology Department, Hospital Universitario San Jorge, Huesca, Spain;

26. Gastroenterology Department, Hospital Universitari Mútua de Terrassa, Terrassa, Spain;

27. Gastroenterology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Madrid, Spain;

28. Gastroenterology Department, Hospital Universitari Dr. Trueta de Girona, Girona, Spain;

29. Gastroenterology Department, Gastroenterology Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain;

30. Gastroenterology Department, Hospital de Granollers, Granollers, Spain;

31. Gastroenterology Department, Complejo Asistencial de Segovia, Segovia, Spain;

32. Gastroenterology Department, Hospital Parc de Salut Mar, Barcelona, Spain;

33. Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.

Abstract

INTRODUCTION: The coexistence of HIV infection and inflammatory bowel disease (IBD) is uncommon. Data on the impact of HIV on IBD course and its management are scarce. The aim of this study was to describe the IBD phenotype, therapeutic requirements, and prevalence of opportunistic infections (OIs) in IBD patients with a coexistent HIV infection. METHODS: Case-control, retrospective study includes all HIV-positive patients diagnosed with IBD in the Nationwide study on genetic and environmental determinants of inflammatory bowel disease registry. Patients with positive HIV serology (HIV-IBD) were compared with controls (HIV seronegative), matched 1:3 by year of IBD diagnosis, age, sex, and type of IBD. RESULTS: A total of 364 patients (91 HIV-IBD and 273 IBD controls) were included. In the whole cohort, 58% had ulcerative colitis, 35% had Crohn's disease (CD), and 7% were IBD unclassified. The HIV-IBD group presented a significantly higher proportion of proctitis in ulcerative colitis and colonic location in CD but fewer extraintestinal manifestations than controls. Regarding treatments, nonbiological therapies (37.4% vs 57.9%; P = 0.001) and biologicals (26.4% vs 42.1%; P = 0.007), were used less frequently among patients in the HIV-IBD group. Conversely, patients with HIV-IBD developed more OI than controls, regardless of nonbiological therapy use. In the multivariate analysis, HIV infection (odds ratio 4.765, 95% confidence interval (CI) 2.48–9.14; P < 0.001) and having ≥1 comorbidity (OR 2.445, 95% CI 1.23–4.85; P = 0.010) were risk factors for developing OI, while CD was protective (OR 0.372, 95% CI 0.18–0.78; P = 0.009). DISCUSSION: HIV infection seems to be associated with a less aggressive phenotype of IBD and a lesser use of nonbiological therapies and biologicals but entails a greater risk of developing OI.

Funder

AbbVie

Takeda Pharmaceuticals U.S.A.

Pfizer

Eli Lilly and Company

Biogen

Galápagos

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference31 articles.

1. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease;Jostins;Nature,2012

2. Review article: The intersection of mucosal pathophysiology in HIV and inflammatory bowel disease, and its implications for therapy;Ho;Aliment Pharmacol Ther,2014

3. Inflammatory and immunometabolic consequences of gut dysfunction in HIV: Parallels with IBD and implications for reservoir persistence and non-AIDS comorbidities;Alzahrani;EBioMedicine,2019

4. The transcriptome of HIV-1 infected intestinal CD4+ T cells exposed to enteric bacteria;Yoder;Plos Pathog,2017

5. Tissue reservoirs of HIV;Wong;Curr Opin HIV AIDS,2016